In another study, exposure of treatment naïve EGFR-mutant PC-9 NSCLC cells to conditioned media of erlotinib-treated cells also enhanced drug resistance in a STAT3-dependent manner [35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.